 Warfarin
"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.438.150.446.520.914 D03.830.219.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
Coumadine- Coumadine
- Bailly Brand of Warfarin Sodium
Warfant- Warfant
- Antigen Brand of Warfarin Sodium
Coumadin- Coumadin
- Goldshield Brand of Warfarin Sodium
- Marevan
- Boots Brand of Warfarin Sodium
- Bristol-Myers Squibb Brand of Warfarin Sodium
Aldocumar- Aldocumar
- Aldo Brand of Warfarin Sodium
Tedicumar- Tedicumar
- Estedi Brand of Warfarin Sodium
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in UAMS Profiles by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2022 | 1 | 0 | 1 | | 2021 | 2 | 1 | 3 | | 2020 | 1 | 1 | 2 | | 2019 | 3 | 0 | 3 | | 2018 | 3 | 0 | 3 | | 2017 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2015 | 2 | 1 | 3 | | 2014 | 3 | 0 | 3 | | 2013 | 2 | 0 | 2 | | 2012 | 1 | 1 | 2 | | 2011 | 4 | 0 | 4 | | 2010 | 4 | 1 | 5 | | 2009 | 1 | 0 | 1 | | 2008 | 2 | 2 | 4 | | 2007 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2002 | 1 | 1 | 2 | | 1994 | 1 | 0 | 1 | | 1992 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Warfarin" by people in Profiles over the past ten years.
-
Coylewright M, Holmes DR, Kapadia SR, Hsu JC, Gibson DN, Freeman JV, Yeh RW, Piccini JP, Price MJ, Allocco DJ, Nair DG. DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis. JACC Cardiovasc Interv. 2023 11 27; 16(22):2708-2718.
-
Bhatia K, Ladd LM, Carr KH, Di Napoli M, Saver JL, McCullough LD, Hosseini Farahabadi M, Alsbrook DL, Hinduja A, Ortiz Garcia JG, Sabbagh SY, Jafarli A, Divani AA. Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. Curr Neurol Neurosci Rep. 2023 05; 23(5):235-262.
-
Levine GN, McEvoy JW, Fang JC, Ibeh C, McCarthy CP, Misra A, Shah ZI, Shenoy C, Spinler SA, Vallurupalli S, Lip GYH. Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association. Circulation. 2022 10 11; 146(15):e205-e223.
-
Curtis HJ, MacKenna B, Walker AJ, Croker R, Mehrkar A, Morton C, Bacon S, Hickman G, Inglesby P, Bates C, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson E, Hulme W, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wong AY, Forbes H, Parry J, Hester F, Harper S, Douglas I, Smeeth L, Goldacre B. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart. 2021 11; 8(2).
-
Briggler R, Matherne E, Johnson C, Boehmer K. Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy. J Pharm Pract. 2022 Oct; 35(5):811-816.
-
Rech MA, Masic D, Hammond DA. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. West J Emerg Med. 2021 Feb 26; 22(2):163-169.
-
Yaghi S, Mistry E, Liberman AL, Giles J, Asad SD, Liu A, Nagy M, Kaushal A, Azher I, Mac Grory B, Fakhri H, Brown Espaillat K, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Scher E, Trivedi T, Lord A, Furie K, Keyrouz S, Nouh A, Leon Guerrero CR, de Havenon A, Khan M, Henninger N. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. Stroke. 2020 09; 51(9):2724-2732.
-
Yaghi S, Liberman AL, Henninger N, Grory BM, Nouh A, Scher E, Giles J, Liu A, Nagy M, Kaushal A, Azher I, Fakhri H, Espaillat KB, Asad SD, Pasupuleti H, Martin H, Tan J, Veerasamy M, Esenwa C, Cheng N, Moncrieffe K, Moeini-Naghani I, Siddu M, Trivedi T, Ishida K, Frontera J, Lord A, Furie K, Keyrouz S, de Havenon A, Mistry E, Leon Guerrero CR, Khan M. Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation. J Stroke Cerebrovasc Dis. 2020 Jul; 29(7):104888.
-
Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 04 01; 3(4):e202175.
-
Reilly RF, Jain N. Warfarin in nonvalvular atrial fibrillation-Time for a change? Semin Dial. 2019 11; 32(6):520-526.
-
Kattoor AJ, Pothineni NV, Goel A, Syed M, Syed S, Paydak H, Mehta JL. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis. J Cardiovasc Pharmacol Ther. 2019 09; 24(5):428-434.
-
Patel DM, Patel MV, Patel AD, Kaklotar JC, Patel GR, Patel MM. Non-uremic Calciphylaxis: A Rare and Late Adverse Reaction of Warfarin. Curr Drug Saf. 2019; 14(3):246-248.
-
Pouncey DL, Hartman JH, Moore PC, Dillinger DJ, Dickerson KW, Sappington DR, Smith ES, Boysen G, Miller GP. Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients. Blood Coagul Fibrinolysis. 2018 Nov; 29(7):602-612.
-
Ghannam M, Chugh A, Dillon P, Alyesh D, Kossidas K, Sharma S, Coatney J, Atreya A, Yokokawa M, Saeed M, Cunnane R, Ghanbari H, Latchamsetty R, Crawford T, Jongnarangsin K, Bogun F, Pelosi F, Morady F, Oral H. Protamine to expedite vascular hemostasis after catheter ablation of atrial fibrillation: A randomized controlled trial. Heart Rhythm. 2018 11; 15(11):1642-1647.
-
Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2019 02 07; 14(2):278-287.
-
Kim SY, Jones DR, Kang JY, Yun CH, Miller GP. Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin. Xenobiotica. 2019 Apr; 49(4):397-403.
-
Pritchard ER, Murillo JR, Putney D, Hobaugh EC. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. J Oncol Pharm Pract. 2019 Jan; 25(1):52-59.
-
Barnette DA, Johnson BP, Pouncey DL, Nshimiyimana R, Desrochers LP, Goodwin TE, Miller GP. Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases. Drug Metab Dispos. 2017 09; 45(9):1000-1007.
-
Casserly EA, Rogers SE, Keisner SV. Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient. J Oncol Pharm Pract. 2017 Jan; 23(1):68-70.
-
Ayoub K, Nairooz R, Almomani A, Marji M, Paydak H, Maskoun W. Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary Interruption of Anticoagulation: Evidence from Meta-analysis. J Stroke Cerebrovasc Dis. 2016 Sep; 25(9):2215-21.
-
Shah A, Shewale A, Hayes CJ, Martin BC. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2016 06; 47(6):1555-61.
-
Price ET. Warfarin pharmacogenomics and African ancestry. Blood. 2015 Jul 23; 126(4):434-6.
-
Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H. Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol. 2015; 187:426-9.
-
Pemberton JD, MacIntosh PW, Zeglam A, Fay A. Naphazoline as a confounder in the diagnosis of carotid artery dissection. Ophthalmic Plast Reconstr Surg. 2015 Mar-Apr; 31(2):e33-5.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|